Fmr LLC Adc Therapeutics Sa Transaction History

Fmr LLC

$1.49 Trillion
Q1 2025

A detailed history of Fmr LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Fmr LLC holds 136,416 shares of ADCT stock, worth $421,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares

136,416

Previous 127,019 7.4%

Holding current value

$421,525

Previous $252,000 23.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$1.39 - $2.02 $13,061 - $18,981	9,397 Added 7.4%	136,416 $192,000
Q4 2024 Feb 13, 2025	BUY	$1.89 - $3.48 $139,816 - $257,439	73,977 Added 139.47%	127,019 $252,000
Q3 2024 Nov 13, 2024	BUY	$2.59 - $4.01 $137,378 - $212,698	53,042 New	53,042 $167,000
Q4 2023 Feb 13, 2024	SELL	$0.47 - $1.79 $615 - $2,343	-1,309 Reduced 99.54%	6 $0
Q3 2023 Nov 13, 2023	SELL	$0.72 - $2.37 $48 - $158	-67 Reduced 4.85%	1,315 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.9 - $2.66 $74,217 - $103,904	-39,062 Reduced 96.58%	1,382 $2,000
Q1 2023 May 11, 2023	SELL	$1.92 - $5.45 $8.86 Million - $25.1 Million	-4,613,009 Reduced 99.13%	40,444 $78,000
Q4 2022 Feb 13, 2023	SELL	$2.87 - $5.24 $8.67 Million - $15.8 Million	-3,019,684 Reduced 39.35%	4,653,453 $17.9 Million
Q3 2022 Nov 10, 2022	SELL	$4.66 - $10.31 $36,855 - $81,541	-7,909 Reduced 0.1%	7,673,137 $37 Million
Q1 2022 May 13, 2022	BUY	$13.28 - $20.03 $111,193 - $167,711	8,373 Added 0.11%	7,681,046 $113 Million
Q2 2021 Aug 13, 2021	BUY	$20.38 - $27.04 $156 Million - $207 Million	7,672,673 New	7,672,673 $187 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

53.9M

Call Options Held

Put Options Held

7.6K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $240M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account